Arre bhai, ek JAMA paper mein kaha gaya hai ki 2030 tak AI Doctors, humans ko diagnosis aur treatment mein maat de sakte hain. Matlab, kuch tasks mein insaano ki zaroorat shayad khatam ho jaye. Efficiency badhegi par 'deskilling' ka risk bhi hai. Investors ke liye ye regulatory frameworks, liability aur healthcare chains par bada sawaal hai.
Naya JAMA perspective paper aya hai bhai, aur medical field mein sab chauk gaye hain. Authors, jismein Ezekiel Emanuel aur Vinod Khosla jaise log hain, keh rahe hain ki 2030 tak AI critical tasks jaise patient data check karna, bimari diagnose karna aur treatment plan banana mein humans se aage nikal jayega.
Abhi tak hum 'human-in-the-loop' model ki baat karte the, jahan AI sirf help karta hai, replace nahi. Lekin ye paper data dikha raha hai ki OpenAI ka o3 aur Google ka AMIE jaise AI models, licensed doctors se better diagnosis aur cost-efficiency mein hain. Kuch cases mein toh human intervention ne AI ki effectiveness kam kar di.
Investors ke liye, especially healthcare diagnostic chains, hospital networks aur health-tech firms mein, ye bahut important hai. Agar AI hi standard ho gaya, toh business model labor-intensive se technology-led ho jayega. Isse costs kam hongi aur accuracy badhegi, jo healthcare mein profit ke liye zaroori hai.
Par mushkilein bhi hain. JAMA paper 'deskilling' ka risk bhi bata raha hai, matlab doctors shayad AI par itna depend ho jayen ki khud kuch kaam karna bhool jayen. Investment ke hisab se ye complicated hai. Agar hospital ya diagnostic chain AI par high-stakes decisions ke liye rely karegi, toh legal aur liability risks bahut hain. Agar AI se galti hui toh zimmedaar kaun?
Regulatory readiness bhi ek bada factor hai. Abhi health authorities AI in medicine ke liye frameworks bana rahi hain. Investors ko dekhna hoga ki future guidelines fully autonomous decision-making ko allow karti hain ya human supervision compulsory rakhti hain. Aur haan, purane hospital systems mein in advanced models ko integrate karne mein kaafi paisa lagega, jisse short-term mein profit margins par pressure aa sakta hai.
Ye study future ki jhalak zarur dikhati hai, par real-world mein iska use abhi time lega. Investors pilot programs, regulatory policy updates aur diagnostic firms kaise tech aur human expertise ko balance karte hain, us par nazar rakh sakte hain. Asli value tabhi pata chalegi jab ye systems patient care ki quality maintain karte hue safely implement ho jayenge.